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The ancient (AD 300) practice of faecal microbiota transplant (FMT) 
corrects dysbiosis (quantitative, qualitative, metabolic or locational 
imbalance of gastrointestinal commensals) by repopulation with 
normal intestinal microbiota. Clostridium difficile infection (CDI) is 
a serious and increasingly prevalent healthcare-associated disease.[1] 
The efficacy of FMT for recurrent CDI is crucial proof of concept that 
therapeutic modification of the gastrointestinal microbiome can be an 
effective treatment modality for human disease.[2] 
In the past, metronidazole and vancomycin were the mainstay of 
CDI treatment, but outcomes with metronidazole are suboptimal 
and it has been superseded by more effective but expensive agents 
such as fidaxomicin.[2] Other novel agents such as bezlotoxumab,[3] 
a monoclonal antibody for the prevention of recurrent CDI, are also 
mostly unaffordable for resource-constrained healthcare sectors in 
South Africa (SA). FMT efficacy has been confirmed in recurrent CDI 
and has the added advantage that it is relatively inexpensive.[4] 
FMT involves the introduction of microbiota from a healthy donor 
to a patient by colonoscopy, enema or nasogastric tube.[5] Currently, 
CDI is the main indication for FMT, but as a novel treatment strategy, 
it has also been investigated in conditions ranging from inflammatory 
bowel disease to metabolic diseases, obesity, malnutrition and autism 
spectrum disorders.[6] To this end, the SA Gastroenterology Society 
(SAGES) published FMT guidelines in 2015.[7] 
The procedure is being performed in the private and public sectors 
in SA. As there is no established national gastrointestinal microbiome 
bank, such as OpenBiome,[8] a non-profit stool bank in the USA with 
the aim of expanding safe access to faecal transplants, it appears that 
currently healthcare providers mostly use stool from close family and 
friends and rarely from unrelated donors. Although experiences with 
FMT in SA are mostly unknown, a recent study from Johannesburg 
demonstrated that at least 70% of donors were close relatives.[9] 
The article highlights the multiple challenges we face, including the 
pertinent discussion on what constitutes an ideal donor and the 
minimal screening tests required for all stool donors in SA. To date, 
there have been no trials evaluating outcomes of faecal transplant in 
relation to donor characteristics.[10] 
Therefore, current criteria for selection and screening of faecal 
donors are primarily a product of expert opinion. While detailed 
protocols that describe FMT administration and consensus reports 
on overall good conduct exist abroad, regulatory challenges and 
uncertainty still prevail – not only in SA, but also abroad. Perhaps 
one reason for lack of a legal framework relates to the urgent need for 
complete methodological reporting for clinical trials and interventions 
involving FMT. A recent systematic review (conducted rigorously 
under PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses) guidelines) of methods and studies assessing FMT, 
highlighted that key components of FMT interventions, which are 
necessary to replicate and understand study findings regarding efficacy 
and safety, are poorly reported.[11]
In addition to the abovementioned regulatory issues, it is being 
debated whether FMT should be regulated as a drug or a tissue. 
However, neither of these established regulatory schemas applies 
clearly to the use of faeces as a therapy. The standard regulatory 
pathways governing traditional drugs are therefore inappropriate. 
Obtaining approval via the drug regulatory pathway will create a 
myriad of problems unsolvable in the medium term. The SA Health 
Products Regulatory Authority (SAHPRA) proposes that a drug 
should be: (i) identical in active ingredient; (ii) consistent with 
regard to the concentration, quality and performance characteristics; 
and (iii) universal in dosage and route of administration. Given the 
extraordinary diversity of the microbiome, conventional labelling does 
not apply. 
We therefore propose a multidisciplinary intersectorial biobank 
working group (WG) for SA, comprising experts in the fields of clinical 
microbiology, gastroenterology, infectious diseases and bioinformatics, 
who could dictate policy and implementation. Safe and reproducible 
methods for donor screening, laboratory processing, funding and 
clinical application of FMT are warranted locally, and probably 
necessitate establishment of a consensus clinical framework for a stool 
bank. The framework could be divided into main-activity sections such 
as donor recruitment (i.e. screening, exclusion criteria), laboratory 
processing of donor material (e.g. initial handling, cryopreservation 
and thawing for clinical application), clinical application (i.e. routes, 
safety) and donor-recipient data management. Stool banks should only 
provide access to screened stool that can be traced to the donor and for 
documenting adverse events in the short, medium and long term.[12] 
This division provides a practical organisational structure and clarifies 
both the tasks and the necessary personnel to maintain an operational 
stool bank nationally or regionally. 
Another advantage of an SA WG relates to several studies of FMT 
that have performed molecular analysis of the microbiota; therefore, 
centralised biorepositories or data repositories could be established to 
enable collective assessment of the effect of FMT on microbiota. This 
could facilitate an understanding of the rationale for this treatment and 
lead to refinement of microbiome-based therapies. Globally, systematic 
analysis of gastrointestinal metagenomics in defined hospitalised 
patients and understanding of the potential protective, metabolic and 
immune functions and hazards associated with its manipulation via 
FMT, are required to support the current framework established by 
regulatory agencies.
The authors believe that systematic appraisal by the proposed 
WG of the evolving body of scientific FMT research is needed 
to inform development of stool banks and guide evidence-based 
clinical best practices in SA. We propose this to constitute the only 
manner to facilitate introduction of potentially multiple cost-effective 
novel management and infection control interventions in resource-
constrained settings.
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